VentriPoint Diagnostics Ltd (TSE:VPT)
:VPT
Want to see TSE:VPT full AI Analyst Report?
Top Page
VentriPoint Diagnostics
(VPT)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.14
▲(20.00% Upside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial fundamentals—especially negative equity, rising leverage, and persistent cash burn—despite strong recent revenue growth. Technical indicators are comparatively supportive (price above major moving averages with positive MACD), but valuation remains constrained by ongoing losses and lack of dividend support.
Positive Factors
Strong revenue acceleration
A ~245% revenue increase in 2025 signals meaningful market traction and product adoption. Durable top-line growth provides the base for scaling fixed-cost absorption and pursuing operating leverage over months, improving the odds of converting growth into sustainable profits if execution continues.
Negative Factors
Deeply negative equity
Negative equity (~-$4.1M) reflects cumulative losses and undermines the capital base. This structural weakness limits borrowing capacity, elevates refinancing and covenant risk, and makes the company reliant on external capital or dilution to fund growth, constraining long-term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue acceleration
A ~245% revenue increase in 2025 signals meaningful market traction and product adoption. Durable top-line growth provides the base for scaling fixed-cost absorption and pursuing operating leverage over months, improving the odds of converting growth into sustainable profits if execution continues.
Read all positive factors
VentriPoint Diagnostics (VPT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$27.21M
Dividend YieldN/A
Average Volume (3M)106.78K
Price to Earnings (P/E)―
Beta (1Y)-0.45
Revenue Growth89.06%
EPS Growth37.62%
CountryCA
Employees10
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,659,200
10 Day Avg. Volume85,718
30 Day Avg. Volume106,775
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)-5.63
Price to Sales (P/S)128.71
P/FCF Ratio-14.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
VentriPoint Diagnostics Business Overview & Revenue Model
Company Description
Ventripoint Diagnostics Ltd., a medical device company, develops and commercializes diagnostic tools that monitor patients with heart disease worldwide. The company offers Ventripoint Medical System (VMS), a medical imaging system that is used to ...
How the Company Makes Money
null...
VentriPoint Diagnostics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 179.93K | 95.17K | 49.18K | 68.17K | 0.00 |
| Gross Profit | 118.69K | 95.17K | 42.43K | 57.81K | -48.81K |
| EBITDA | -3.34M | -4.76M | -4.74M | -4.79M | -3.81M |
| Net Income | -3.20M | -4.92M | -4.87M | -4.87M | -3.88M |
Balance Sheet | |||||
| Total Assets | 472.08K | 658.02K | 1.88M | 5.98M | 9.54M |
| Cash, Cash Equivalents and Short-Term Investments | 55.39K | 60.55K | 1.29M | 5.19M | 9.27M |
| Total Debt | 2.60M | 1.63M | 412.44K | 459.08K | 159.97K |
| Total Liabilities | 4.59M | 3.64M | 1.69M | 1.42M | 1.21M |
| Stockholders Equity | -4.12M | -2.98M | 189.71K | 4.55M | 8.33M |
Cash Flow | |||||
| Free Cash Flow | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Operating Cash Flow | -1.55M | -3.39M | -3.80M | -4.14M | -3.15M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -4.26K |
| Financing Cash Flow | 1.53M | 2.20M | -102.36K | 87.65K | 11.89M |
VentriPoint Diagnostics Technical Analysis
Negative
0.12
Price Trends
0.11
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
36.12
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VPT, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.11, above the 50-day MA of 0.11, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 36.12 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VPT.
VentriPoint Diagnostics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | C$345.57M | -11.64 | -72.79% | ― | 57.39% | -2.20% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$38.46M | -5.70 | -258.64% | ― | 176.72% | 30.90% | |
49 Neutral | C$27.21M | -7.24 | 106.68% | ― | 89.06% | 37.62% | |
42 Neutral | C$59.12M | -10.14 | -314.74% | ― | -20.99% | 9.39% |
* Healthcare Sector Average
TSE:VPT
VentriPoint Diagnostics
0.15
0.02
16.00%
TSE:IME
Imagin Medical
0.02
0.00
0.00%
TSE:PINK
Perimeter Medical Imaging AI
0.31
-0.14
-30.68%
TSE:PRN
Profound Medical
9.51
2.55
36.64%
TSE:TLT
Theralase Technologies
0.23
0.05
27.78%
VentriPoint Diagnostics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Ventripoint to Expand AI Cardiac Imaging in Costa Rica via Montecristo Partnership
Positive
Apr 1, 2026
Ventripoint Diagnostics has entered a collaboration with the Health Division of Costa Rica’s Montecristo Group to explore deploying its VMS+ AI-assisted cardiac imaging platform across the country’s healthcare network. The initiative t...
Business Operations and StrategyProduct-Related Announcements
Ventripoint and First Light Health Launch AI Cardiac Imaging Network for Remote Indigenous Communities
Positive
Mar 17, 2026
Ventripoint Diagnostics has partnered with Indigenous-owned First Light Health to deploy its AI-assisted VMS+ cardiac imaging system in a hub-and-spoke network serving Indigenous and remote communities across British Columbia and other Canadian re...
Business Operations and StrategyPrivate Placements and Financing
Ventripoint Uses Shares to Pay Debenture Interest as Conversions Trim Future Obligations
Positive
Mar 4, 2026
Ventripoint Diagnostics has issued 291,344 common shares, valued at a deemed price of $0.127, to settle $36,989.01 in interest owed on several outstanding convertible debenture series, following approval from the TSX Venture Exchange. The shares, ...
Business Operations and StrategyProduct-Related Announcements
Ventripoint Taps LG Consulting to Drive VMS+ Rollout in Northern California
Positive
Mar 3, 2026
Ventripoint Diagnostics has signed a memorandum of understanding and consulting agreement with LG Consulting Solutions to support commercialization and deployment of its VMS+ AI-enhanced echocardiography system in Northern California. LG Consultin...
Business Operations and StrategyPrivate Placements and FinancingProduct-Related AnnouncementsShareholder Meetings
Ventripoint Advances VMS+ Commercialization and Sets Shareholder Update Call
Positive
Feb 20, 2026
Ventripoint Diagnostics reported continued execution of its commercialization strategy for the VMS+ cardiac imaging platform, highlighting refined U.S. go-to-market plans, active customer engagement, and strengthened distributor partnerships in Eu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.